{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:37:05Z","timestamp":1793284625208,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.hrtlng.2026.102959","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:16:42Z","timestamp":1790817402000},"page":"102959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-049X","authenticated-orcid":false,"given":"Melike Nur","family":"Akba\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-3154","authenticated-orcid":false,"given":"Zinnet \u015eevval","family":"Aksoyalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2026.102959_bib0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0002","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0003","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-024-00653-6","article-title":"Safety of biological therapies for severe asthma: an analysis of suspected adverse reactions reported in the WHO pharmacovigilance database","volume":"38","author":"Cutroneo","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s40124-025-00373-7","article-title":"Biologic therapies in severe asthma: current landscape, clinical evidence, and future directions","volume":"13","author":"Okuducu","year":"2025","journal-title":"Curr Pediatr Rep"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0007","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.alit.2022.11.006","article-title":"Current summary of clinical studies on anti-TSLP antibody, tezepelumab, in asthma","volume":"72","author":"Kurihara","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/1806-9282.20221358","article-title":"Anaphylactic risks associated with immunobiological agents in asthma therapy","volume":"69","author":"Baddini-Martinez","year":"2023","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0009","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/all.15008","article-title":"Potential cancer risk with omalizumab? a disproportionality analysis of the WHO's VigiBase pharmacovigilance database","volume":"76","author":"Mota","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0010","unstructured":"FDA. FDA Drug Safety Communication: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. 2014."},{"key":"10.1016\/j.hrtlng.2026.102959_bib0011","unstructured":"MHRA. Omalizumab: potential risk of arterial thrombotic events. 2014."},{"key":"10.1016\/j.hrtlng.2026.102959_bib0012","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaip.2020.12.031","article-title":"Cardiovascular adverse effects of anti-IL-5\/IL-5Ralpha therapies: a real-world study","volume":"9","author":"Quinta","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S29811","article-title":"Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting","volume":"5","author":"Ali","year":"2012","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0014","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA adverse event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"Douglas G Altman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0016","series-title":"The EQUATOR Network Reporting Guideline Platform","article-title":"The STROBE reporting checklist","author":"Elm","year":"2025"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0018","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1081-1206(10)60184-6","article-title":"Baseline characteristics of patients enrolled in EXCELS: a cohort study","volume":"103","author":"Long","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0020","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0021","article-title":"A case of pulmonary vein thrombosis associated with treatment of Omalizumab","volume":"5","author":"Narukonda","year":"2017","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1177392819861987","article-title":"Omalizumab as a provoking factor for venous thromboembolism","volume":"13","author":"Oblitas","year":"2019","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0023","article-title":"Cardiovascular safety of biologic therapies in patients with severe asthma: a nationwide cohort study in Belgium","volume":"57","author":"Van Vaerenbergh","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0024","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0025","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/emmm.201201374","article-title":"Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype","volume":"4","author":"Cardilo-Reis","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0026","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1074248419868699","article-title":"Interleukin 4: its role in hypertension, atherosclerosis, valvular, and nonvalvular cardiovascular diseases","volume":"25","author":"Kassem","year":"2020","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0027","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.2147\/JIR.S531346","article-title":"IL-4 and IL-13 in cardiovascular disease: from immune modulation to therapeutic possibilities - a narrative review","volume":"18","author":"Kilic","year":"2025","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/allergies6010010","article-title":"Cardiovascular safety of dupilumab: current evidence and emerging concerns","volume":"6","author":"Laterra","year":"2026","journal-title":"Allergies"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0029","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2024.04.033","article-title":"MELTEMI and COLUMBA: 5-year comparative safety analysis of benralizumab and mepolizumab","volume":"12","author":"Bourdin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0030","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of Mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0031","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of Mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1280490","article-title":"A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.hrtlng.2026.102959_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956326002438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956326002438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:12:39Z","timestamp":1793283159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956326002438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0147956326002438"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2026.102959","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2026.102959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102959"}}